Business context and reporting period
Fluidigm Corporation’s unaudited Form 10-Q covers the quarter and six months ended June 30, 2012. The filing describes a business developing, manufacturing and selling microfluidic instruments and consumables for life-science and agricultural-biotechnology markets. The request metadata names STANDARD BIOTOOLS INC., but the registrant identified in this filing is FLUIDIGM CORPORATION; verify the company and filing identity.
Financial performance and position
Amounts below are in U.S. dollars; financial statement amounts are in millions unless otherwise noted.
| Metric | Three months ended June 30, 2012 | Six months ended June 30, 2012 |
|---|---|---|
| Total revenue | $12.95 million, up 22% year over year | $23.89 million, up 24% |
| Product revenue | $12.77 million, up 31% | $23.52 million, up 30% |
| Product margin | 69%, unchanged | 68%, unchanged |
| Operating loss | $4.39 million, versus $6.65 million | $10.67 million, versus $11.53 million |
| Net loss | $4.58 million, versus $7.19 million | $11.27 million, versus $14.52 million |
| Net loss per share | $0.22 | $0.55 |
| Operating cash flow | Not presented for the quarter | Cash used: $10.64 million, versus $12.91 million |
For the quarter, consumables revenue rose 79% to $5.87 million, while instrument revenue increased 7% to $6.90 million. For the first half, consumables rose 59% to $10.73 million and instruments rose 12% to $12.80 million. The filing attributes consumables growth mainly to production genotyping chips, alongside increased chip pull-through and a larger installed instrument base.
At June 30, cash and cash equivalents were $9.85 million and investments were $29.02 million. Working capital was $40.9 million. Total assets were $64.93 million and total liabilities $16.01 million. Debt included $2.83 million under the loan agreement, classified as current, and $1.88 million drawn on the revolving line of credit; the line permits borrowing up to $7 million, subject to covenants. The company reported compliance with both debt agreements’ covenants.
Material changes versus prior comparable periods
- Revenue growth was led by product sales, while license and collaboration revenue fell to $15,000 for the quarter and $38,000 for the half-year, compared with $754,000 and $921,000, respectively, in 2011.
- Operating expenses excluding the prior-year litigation settlement increased: R&D rose 17% in the quarter and 24% in the half-year; SG&A rose 20% and 23%, respectively. The 2011 comparison included a $3.0 million litigation settlement charge, absent in 2012.
- Interest expense declined to $0.20 million for the quarter and $0.51 million for the half-year, partly reflecting debt repayments and the absence of the prior-year note discount write-off. The 2011 half-year also included preferred-warrant valuation items and a $9.9 million deemed dividend affecting loss attributed to common stockholders.
- Cash and investments totaled $38.9 million at June 30, down from $55.0 million at December 31, 2011. Cash and cash equivalents alone decreased by $3.70 million during the first half.
Outlook, commentary, risks and unusual items
- Management expected instrument and consumables unit sales to grow over time as it expanded customer and geographic coverage and launched products; it cautioned that selling prices could fluctuate. No quantified revenue or earnings guidance was provided.
- Management expected R&D and SG&A costs to increase with product development, public-company costs and expansion of global commercial capabilities. Capital expenditures were expected to be higher in 2012 than in 2011.
- The company estimated existing cash, cash equivalents and investments would cover working-capital and capital-expenditure needs for at least 18 months. It warned that weaker cash generation or higher spending could require additional financing, which might be unavailable or dilute shareholders.
- Fluidigm launched its C1 Single-Cell AutoPrep system in June 2012. The company identified market acceptance, competition, product development, manufacturing yields, supplier concentration, international exposure, regulatory changes and intellectual-property claims as significant risks.
- The Novartis collaboration option expired unexercised on April 30, 2012, and the agreement terminated effective May 1; related rights reverted to Fluidigm. The filing says entry into diagnostics markets could be delayed or might not occur.
- Following its 2011 settlement with Life Technologies, Fluidigm had paid $3.0 million for the settlement and a further $2.0 million to limit certain litigation rights. No material legal proceedings were reported, and no legal-contingency accrual was recorded at June 30, 2012.
- Management concluded disclosure controls were effective at a reasonable-assurance level. An ERP system implementation was underway; the company reported no material control changes other than the implementation.
Important facts for investors to verify
- Confirm that this Fluidigm 2012 filing is the intended company and period, given the mismatch with the request metadata.
- Track whether consumables-led growth continues and whether it supports sustained product margins and lower operating losses.
- Compare cash burn and planned capital expenditures with the stated 18-month liquidity expectation; monitor debt maturity and available line-of-credit capacity.
- Assess whether the C1 launch and other product development translate into customer adoption, and whether the loss of the Novartis collaboration affects diagnostics plans.
- Monitor manufacturing capacity, single-source suppliers, regulatory exposure and intellectual-property developments, including the requested continuation of the domestic-manufacturing waiver for licensed technology.